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Abstract: Finding cytotoxic drugs with a high selectivity towards cancer cells is crucial to improve
the low survival rates of patients diagnosed with metastatic cancers. Since plants are an important
source of anticancer drugs, we have screened 65 extracts from 45 plants collected in several areas
of Western Andalusia (Spain) for cytotoxic activity on lung cancer cells versus lung normal cells.
An extract from the leaves of Tetraclinis articulata (Vahl) Mast. (Cupressaceae) showed a marked
cytotoxicity (IC50 = 0.37 ± 0.03 µg/mL) and selectivity (selectivity index = 378.3) against the lung
cancer cells; cisplatin, 5-fluorouracil, and an extract from the leaves of Taxus baccata L. (Taxaceae) were
less cytotoxic and selective. Extracts from Cascabela thevetia (L.) Lippold (Apocynaceae), Frangula
alnus Mill. (Rhamnaceae), Iberis ciliata subsp. contracta (Pers.) Moreno (Brassicaceae), Juniperus
macrocarpa Sm (Cupressaceae), and Pancratium maritimum L. (Amaryllidaceae) also showed selective
cytotoxicity (selectivity index > 10). Active extracts were also tested against a panel of cancer cell lines
from a variety tissues. The plants identified in this work are potential sources of natural compounds
with selective toxicity towards cancer cells.
Keywords: cancer; lung cancer; selectivity; Tetraclinis articulata (Vahl) Mast.; Cupressaceae
1. Introduction
Despite the recent approval of new anticancer treatments, metastasis continues to be
an incurable disease for most cancer patients. The limited efficacy of the existing therapies is
reflected in the poor survival rates of patients diagnosed with the most common metastatic
cancers [1]. For example, distant metastases occur in 57% of patients diagnosed with lung
cancer, and only 6% of them survive 5 years after diagnosis [1]. The percentages are also
low for other common metastatic cancers. The five-year relative survival rates for patients
with distant metastases are 30% in prostate cancer, 28% in breast cancer, 14% in colorectal
cancer, 27% in melanoma, 13% in renal cancer, 30% in ovarian cancer, 17% in cancers of the
uterine corpus, 17% in cancers of the uterine cervix, 6% in bladder cancer, 5% in esophageal
cancer, 3% in liver cancer, and 3% in pancreatic cancer [1]. Many patients with metastases
do not overcome the disease despite surviving five years after diagnosis.
Understanding why the current treatments rarely cure patients with disseminated
disease is important to discover better therapies. When one treats cancer cells with spe-
cific concentrations of the available anticancer drugs and examines the cells under the
microscope, one generally observes a massacre. All cancer cells die in response to most
treatments. However, these drugs also kill normal cells at similar concentrations. The
consequence of this limited selectivity is that patients cannot receive the drug doses needed
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to kill all their cancer cells; such doses would also kill their normal body cells and would be
lethal. Although oncology patients generally receive the maximum tolerated doses, these
doses are usually insufficient to reach the drug concentrations required to eradicate their
cancer cells. The surviving cancer cells continue to proliferate and eventually lead to a fatal
outcome. Finding drugs with a high selectivity towards cancer cells is crucial to develop
more effective treatments for patients with metastasis [2–4].
Several plants have provided useful drugs for the treatment of a variety of cancers,
including lung cancer [5–7]. For example, the diterpene paclitaxel (isolated from the
bark of Taxus brevifolia Nutt., Taxaceae) and its semisynthetic derivative docetaxel are
FDA-approved drugs for the treatment of non-small-cell lung cancer [8,9]. Vinorelbine,
a semisynthetic analog of the vinca alkaloids (isolated from Catharanthus roseus G. Don.,
Apocynaceae), is also approved for patients with this type of cancer [9]. Etoposide (a
semi-synthetic analogue of the natural lignan podophyllotoxin, isolated from Podophyllum
species, Podophyllaceae) and topotecan (an analogue of the quinoline alkaloid camp-
totethin, isolated from Camptotheca acuminata Decne, Nyssaceae) are approved for patients
with small cell lung cancer. Due to the fact that several plants have provided useful an-
ticancer agents, we recently used lung cancer cells and lung normal cells to evaluate the
selective anticancer activity of 57 extracts from plants collected in Grazalema Natural Park
(Andalusia, Spain) [10]. Using a similar experimental approach, we have evaluated the
selective anticancer activity of 65 extracts from 45 new plants collected in several areas of
Western Andalusia, and report the results in this article.
2. Results and Discussion
Due to the fact that patients with metastatic cancers need selective anticancer drugs,
we have searched for potential sources of selective anticancer drugs in 45 plants growing
in Western Andalusia, Spain. After collecting the plant material and preparing 65 extracts,
we used lung cancer cells (A549) and lung normal cells (MRC-5) to evaluate their selective
cytotoxicity with the MTT assay. A549 cells are epithelial cells and MRC-5 cells are fibrob-
lastic cells. However, since normal epithelial cells are difficult to maintain and expand in
culture, we selected this widely used normal cell line for our screening [11–13].
We exposed both cell lines for 72 h to at least five concentrations of the extracts and
the anticancer drugs cisplatin and 5-fluorouracil (5-FU). Table 1 shows the botanical names
in alphabetical order, the plant families and other pertinent information on the 45 plant
species. It also shows an identification number for each extract, the IC50 value for each
cell line, and the selectivity index. Dose–response curves for the 65 extracts and positive
controls are provided in Figures 1–6; these curves allow for the visualization of their
cytotoxic profile over a wide concentration range.
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Table 1. Cytotoxic activity of plant extracts on lung cancer cells (A549) versus lung normal cells (MRC-5).
Extract Plant Name (Family) Part Used Voucher Number(SEV) Origin
IC50 (MTT)
(Mean ± SEM, µg/mL)
S.I.
(Mean ± SEM)
A549 (Cancer) MRC-5 (Normal)
1 Acis autumnalis (L.) Sweet (Amaryllidaceae) Whole plant 284654 Seville 32.9 ± 9.6 59.1 ± 18.0 1.9 ± 0.6
2 Anagallis monelli L. (Primulaceae) Aerial Parts 284675 Cádiz 3.2 ± 1.4 0.6 ± 0.2 0.3 ± 0.2
3 Anagallis monelli L. (Primulaceae) Root 284675 Cádiz 7.4 ± 5.2 0.9 ± 0.5 0.3 ± 0.3
4 Anthyllis hamosa Desf. (Leguminosae) Whole plant 284685 Huelva 260.9 ± 14.7 317.7 ± 3.1 1.2 ± 0.1
5 Aristolochia baetica L. (Aristolochiaceae) Fruits 284674 Seville 249.1 ± 2.5 649.9 ± 345.0 2.6 ± 1.4
6 Aristolochia baetica L. (Aristolochiaceae) Leaves 284674 Seville 91.8 ± 70.5 66.0 ± 39.9 0.9 ± 0.3
7 Armeria pungens (Link) Hoffmanns. & Link(Plumbaginaceae)
Flowering aerial
parts 284687 Huelva 143.4 ± 64.3 550.7 ± 352.2 3.6 ± 1.1
8 Armeria velutina Welw. ex Boiss. & Reut.(Plumbaginaceae) Whole plant 284689 Huelva 25.7 ± 1.9 36.7 ± 0.9 1.4 ± 0.1
9 Campanula lusitanica L. (Campanulaceae) Whole plant 284667 Seville 223.4 ± 51.2 263.7 ± 34.2 1.3 ± 0.4
10 Cascabela thevetia (L.) Lippold(Apocynaceae) Leaves 284662 Seville 0.14 ± 0.02 1.6 ± 0.5 26.6 ± 11.6
11 Centaurea sphaerocephala L. (Compositae) Whole plant 284683 Huelva 134.2 ± 82.4 160.4 ± 33.8 1.7 ± 0.8
12 Centaurea sphaerocephala L. (Compositae) Flowers 284676 Cádiz 139.1 ± 40.1 108.7 ± 7.7 1.7 ± 1.1
13 Centaurea sphaerocephala L. (Compositae) Leaves 284676 Cádiz 43.1 ± 11.1 114.7 ± 14.4 3.0 ± 0.8
14 Cistus crispus L. (Cistaceae) Leaves 284660 Seville 52.4 ± 5.1 126.4 ± 34.3 2.5 ± 0.7
15 Cistus crispus L. (Cistaceae) Root 284660 Seville 24.9 ± 0.7 58.8 ± 14.8 2.1 ± 0.7
16 Cistus salviifolius L. (Cistaceae) Leaves 284653 Seville 56.6 ± 12.6 142.7 ± 20.4 3.0 ± 0.9
17 Cleome violacea L. (Cleomaceae) Aerial Parts 284668 Seville 253.9 ± 39.9 261.1 ± 3.4 1.1 ± 0.2
18 Digitalis purpurea L. (Plantaginaceae) Leaves 284691 Huelva 0.17 ± 0.15 1.06 ± 0.69 9.3 ± 0.5
19 Dorycnium rectum (L.) Ser. (Leguminosae) Flowers 284690 Seville 102.1 ± 40.2 182.9 ± 46.1 4.3 ± 3.2
20 Dorycnium rectum (L.) Ser. (Leguminosae) Leaves 284690 Seville 293.6 ± 21.2 322.1 ± 27.4 1.1 ± 0.2
21 Echium gaditanum Boiss. (Boraginaceae) Aerial Parts 284684 Huelva 196.1 ± 107.2 325.6 ± 44.0 1.1 ± 0.1
22 Elaeoselinum foetidum (L.) Boiss. (Apiaceae) Flowers 284670 Seville 119.0 ± 16.2 262.1 ± 8.7 2.3 ± 0.3
23 Elaeoselinum foetidum (L.) Boiss. (Apiaceae) Leaves 284670 Seville 246.5 ± 25.5 295.0 ± 36.4 1.2 ± 0.0
24 Erica arborea L. (Ericaceae) Bark 284657 Seville 32.2 ± 5.6 62.1 ± 28.9 1.8 ± 0.7
25 Erica arborea L. (Ericaceae) Leaves 284657 Seville 45.7 ± 7.4 158.4 ± 43.6 3.9 ± 1.4
26 Erophaca baetica (L.) Boiss. (Leguminosae) Leaves 284673 Seville >1000 >1000 N.D.
27 Frangula alnus Mill. (Rhamnaceae) Bark 284680 Huelva 32.8 ± 7.4 339.3 ± 74.1 12.4 ± 3.3
28 Frangula alnus Mill. (Rhamnaceae) Leaves 284680 Huelva 28.6 ± 3.5 74.0 ± 38.5 2.4 ± 1.0
29 Genista hirsuta M.Vahl (Leguminosae) Aereal Parts 284671 Seville 273.6 ± 5.8 363.9 ± 27.9 1.3 ± 0.1
30 Halimium calycinum (L.) K.Koch (Cistaceae) Leaves 284656 Seville 47.4 ± 10.0 135.4 ± 23.6 4.3 ± 1.9
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Table 1. Cont.
Extract Plant Name (Family) Part Used Voucher Number(SEV) Origin
IC50 (MTT)
(Mean ± SEM, µg/mL)
S.I.
(Mean ± SEM)
A549 (Cancer) MRC-5 (Normal)
31 Halimium calycinum (L.) K.Koch (Cistaceae) Root 284656 Seville 60.1 ± 17.7 101.1 ± 13.6 2.2 ± 0.8
32 Halimium halimifolium (L.) Willk. (Cistaceae) Leaves 284659 Seville 47.9 ± 10.9 105.9 ± 21.4 2.7 ± 0.9
33 Halimium halimifolium (L.) Willk. (Cistaceae) Root 284659 Seville 67.5 ± 16.0 110.2 ± 33.4 1.8 ± 0.8
34 Hedysarum coronarium L. (Leguminosae) Flowers 284677 Cádiz 230.5 ± 54.6 306.9 ± 55.1 1.4 ± 0.1
35 Hedysarum coronarium L. (Leguminosae) Fruits 284677 Cádiz 247.0 ± 3.2 294.5 ± 0.4 1.2 ± 0.0
36 Hedysarum coronarium L. (Leguminosae) Leaves 284677 Cádiz 173.9 ± 60.6 262.0 ± 32.3 2.1 ± 0.9
37 Iberis ciliata subsp. contracta (Pers.) Moreno(Brassicaceae) Whole plant 284688 Huelva 0.31 ± 0.06 2.31 ± 0.88 13.0 ± 4.7
38 Jasione montana L. (Campanulaceae) Whole plant 284666 Seville 145.0 ± 26.0 301.6 ± 69.2 2.0 ± 0.1
39 Juniperus macrocarpa Sm. (Cupressaceae) Monosperma cones 284682 Huelva 146.1 ± 125.9 >1000 >20
40 Juniperus macrocarpa Sm. (Cupressaceae) Aerial Parts 284682 Huelva 3.7 ± 1.9 2.8 ± 1.0 0.8 ± 0.1
41 Malcolmia lacera (L.) DC. (Brassicaceae) Whole plant 284664 Seville 322.3 ± 86.7 295.0 ± 5.9 1.0 ± 0.3
42 Malva hispanica L. (Malvaceae) Aerial Parts 284669 Seville >1000 703.1 ± 51.1 N.D.
43 Ononis subspicata Lag. (Leguminosae) Whole plant 284695 Huelva 63.9 ± 23.6 232.3 ± 29.5 4.6 ± 1.4
44 Ornithopus compressus L. (Leguminosae) Whole plant 284693 Seville 340.7 ± 28.4 583.8 ± 150.0 1.8 ± 0.6
45 Ornithopus sativus Brot. (Leguminosae) Whole plant 284692 Seville 326.6 ± 37.5 699.0 ± 262.9 2.3 ± 1.1
46 Pancratium maritimum L. (Amaryllidaceae) Bulb 284681 Huelva 3.4 ± 0.2 74.1 ± 56.1 19.7 ± 14.6
47 Pycnocomon rutifolium (Vahl) Hoffmanns. &Link (Caprifoliaceae) Leaves 284678 Cádiz 71.4 ± 40.4 70.6 ± 18.1 2.2 ± 1.4
48 Pycnocomon rutifolium (Vahl) Hoffmanns. &Link (Caprifoliaceae) Root 284678 Cádiz 262.5 ± 131,9 242.9 ± 56.7 1.1 ± 0.3
49 Ranunculus peltatus Schrank(Ranunculaceae) Whole plant 284672 Seville 186.7 ± 54.6 170.1 ± 58.8 0.9 ± 0.1
50 Rhamnus lycioides subsp. oleoides (L.) Jahand.& Maire (Rhamnaceae) Bark 284655 Seville 332.2 ± 61.9 599.4 ± 122.1 2.1 ± 0.8
51 Rhamnus lycioides subsp. oleoides (L.) Jahand.& Maire (Rhamnaceae) Leaves 284655 Seville 151.5 ± 16.7 421.3 ± 176.5 3.1 ± 1.6
52 Rhamnus lycioides subsp. oleoides (L.) Jahand.& Maire (Rhamnaceae) Root 284655 Seville 257.0 ± 76.6 442.3 ± 35.1 2.3 ± 0.8
53 Scrophularia frutescens L. (Scrophulariaceae) Whole plant 284686 Huelva 281.5 ± 9.2 297.6 ± 8.6 1.1 ± 0.1
54 Stauracanthus genistoides (Brot.) G. Sampaio(Leguminosae) Aerial Parts 284679 Huelva 278.4 ± 32.9 546.5 ± 53.5 2.0 ± 0.4
55 Tamarix canariensis Willd. (Tamaricaceae) Flowers 284650 Seville 212.8 ± 10.2 336.3 ± 3.6 1.6 ± 0.1
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Table 1. Cont.
Extract Plant Name (Family) Part Used Voucher Number(SEV) Origin
IC50 (MTT)
(Mean ± SEM, µg/mL)
S.I.
(Mean ± SEM)
A549 (Cancer) MRC-5 (Normal)
56 Tamarix canariensis Willd. (Tamaricaceae) Leaves 284650 Seville 92.7 ± 24.6 192.1 ± 33.0 2.2 ± 0.3
57 Taxus baccata L. (Taxaceae) Leaves 284621 Seville 0.86 ± 0.27 146.9 ± 87.8 157.3 ± 110.6
58 Tetraclinis articulata (Vahl) Mast.(Cupressaceae) Leaves 284663 Seville 0.37 ± 0.03 129.5 ± 64.0 378.3 ± 178.1
59 Teucrium fruticans L. (Lamiaceae) Leaves 284658 Seville 157.1 ± 30.5 433.0 ± 112.3 2.8 ± 0.7
60 Thymus mastichina (L.) L. (Lamiaceae) Whole plant 284694 Huelva 36.8 ± 7.7 277.7 ± 40.6 8.2 ± 2.0
61 Tolpis barbata (L.) Gaertn. (Compositae) Whole plant 284665 Seville 86.5 ± 28.3 43.7 ± 12.2 0.5 ± 0.0
62 Ulex parviflorus Pourr. subsp. parviflorus(Leguminosae) Flowers 284652 Seville 361.7 ± 89.6 876.1 ± 426.1 4.0 ± 2.9
63 Ulex parviflorus Pourr. subsp. parviflorus(Leguminosae) Leaves 284652 Seville 99.6 ± 34.8 270.4 ± 85.3 3.4 ± 1.2
64 Viburnum tinus L. (Adoxaceae) Fruits 284651 Seville 26.6 ± 6.5 65.4 ± 8.6 2.6 ± 0.3
65 Viburnum tinus L. (Adoxaceae) Leaves 284651 Seville 234.8 ± 58.7 568.2 ± 73.0 2.6 ± 0.3
Cisplatin (Standard anticancer drug) 10.5 ± 5.5 (µM) 25.4 ± 7.4 (µM) 4.2 ± 2.2
5-Fluorouracil (Standard anticancer drug) 101.8 ± 7.7(µM)
>1000
(µM) >9.9
S.I.: selectivity index (calculated as the average of the IC50 value in the MRC-5 normal cell line divided by the IC50 value in the A549 cancer cell line obtained in each independent experiment); Nd: not determined.
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Figure 1. Screening for selective cytotoxic activity of plant extracts 1–12 on A549 lung cancer cells and MRC-5 lung normal
cells. The cells were exposed for 72 h to the extracts and cell viability was determined with the MTT assay.
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Figure 2. Screening for selective cytotoxic activity of plant extracts 13–24 on A549 lung cancer cells and MRC-5 lung normal
cells. The cells were exposed for 72 h to the extracts and cell viability was determined with the MTT assay.
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Figure 3. Screening for selective cytotoxic activity of plant extracts 25–36 on A549 lung cancer cells and MRC-5 lung normal
cells. The cells were exposed for 72 h to the extracts and cell viability was determined with the MTT assay.
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Figure 4. Screening for selective cytotoxic activity of plant extracts 37–48 on A549 lung cancer cells and MRC-5 lung normal
cells. The cells were exposed for 72 h to the extracts and cell viability was determined with the MTT assay.
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Figure 5. Screening for selective cytotoxic activity of plant extracts 49–60 on A549 lung cancer cells and MRC-5 lung normal
cells. The cells were exposed for 72 h to the extracts and cell viability was determined with the MTT assay.
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Figure 6. Screening for selective cytotoxic activity of plant extracts 61–65, cisplatin, and 5-fluorouracil (5-FU) on A549 lung
cancer cells and MRC-5 lung normal cells. The cells were exposed for 72 h to the extracts or anticancer drugs and cell
viability was determined with the MTT assay.
Results show that several extracts induced selective cytotoxicity towards the cancer
cell line, including the extract from the leaves of Cascabela thevetia (L.) Lippold (Apoc-
ynaceae) (10), the extract from the leaves of Digitalis purpurea L. (Plantaginaceae) (18),
the extract from the bark of Frangula alnus Mill. (Rhamnaceae) (27), the extract from
the whole plant Iberis ciliata subsp. contracta (Pers.) Moreno (Brassicaceae) (37), the ex-
tract from the seeds of Juniperus macrocarpa Sm. (Cupressaceae) (39), the extract from
the bulb of Pancratium maritimum L. (Amaryllidaceae) (46), and the extract from the
leaves of Tetraclinis articulata (Vahl) Mast. (Cupressaceae) (58). The anticancer drugs
cisplatin and 5-fluorouracil, and an extract from the leaves of Taxus baccata L. (Taxac-
eae) (57) also showed selectivity against the cancer cells (Table 1). The extract from the
leaves of Tetraclinis articulata (Vahl) Mast. (58) (Figure 5) showed the most relevant activ-
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ity; it was more cytotoxic against the lung cancer cells (IC50 = 0.37 ± 0.03 µg/mL) than
against the lung normal cells (IC50 = 129.5 ± 64.0 µg/mL), displaying a selectivity in-
dex of 378.3 ± 178.1. No significant differences were observed when the cytotoxicity of
this extract was tested with the MTT assay and the resazurin assay (Figure S1). Pho-
tographs of this plant and the plant material used to prepare the extract are shown in
Figure S2. The extract from the leaves of Taxus baccata L. (Taxaceae) was also more cytotoxic
against the lung cancer cells (IC50 = 0.86 ± 0.27 µg/mL) than against the lung normal
cells (IC50 = 146.9 ± 87.8 µg/mL), displaying a selectivity index of 157.3 ± 110.6. Several
extracts (e.g., 4, 6, 9, 11, 12, 17, 20, 23, 34, 35, 41, 42, 48, 49, 53) were cytotoxic but were not
selective against the A549 lung cancer cells.
Extracts (10, 18, 37, 46, 57, and 58), and the anticancer drugs cisplatin and 5-fluorouracil,
were tested with the resazurin assay against eleven additional cell lines: two leukemia cell
lines, six cancer cell lines derived from solid tumors of different tissues (liver, colon, bone,
cervix, prostate, and breast), and three genetically modified skin cell lines with increasing
degrees of malignancy (Table 2 and Figure 7). Due to the fact that the leukemia cell lines
grow in suspension, we determined cell viability with the resazurin assay. Unlike the MTT
assay, this assay does not require removal of the culture medium. The extract from the
leaves of Tetraclinis articulata (Vahl) Mast. (58) displayed the highest cytotoxic activity, with
IC50 values between 0.2 and 2.1 µg/mL against seven of the eight cancer cell lines. No
clear differences in cytotoxicity were found for any extract or compound in the three skin
cell lines with increasing degrees of malignancy (BJ-hTERT, BJ-SV40T, and BJ-RASV12) [14]
(Table 2).
Table 2. Cytotoxicity as IC50 values of selected extracts, cisplatin, and 5-FU on a panel of human cancer cell lines of different
tissue origin and three genetically modified skin cell lines. Values are expressed as mean ± SEM.
IC50 (Resazurin)
(Mean ± SEM, µg/mL)
IC50 (Resazurin)
(Mean ± SEM, µM)
Cell Line 10 18 37 46 57 58 Cisplatin 5-FU
HepG2 24.6 ± 4.1 13.2 ± 3.0 19.4 ± 10.4 7.0 ± 1.3 632.6 ± 106.1 18.4 ± 17.1 3.5 ± 0.8 0.3 ± 0.2
SW480 20.7 ± 5.6 18.3 ± 1.2 1.2 ± 0.3 2.1 ± 0.4 2.2 ± 0.7 2.1 ± 0.8 2.0 ± 0.5 3.4 ± 1.0
U2OS 9.2 ± 1.5 8.8 ± 0.8 1.9 ± 0.2 2.8 ± 0.7 4.0 ± 1.2 2.1 ± 0.9 4.0 ± 1.0 7.2 ± 1.0
HeLa 4.7 ± 0.1 4.9 ± 0.2 3.5 ± 0.5 5.4 ± 0.4 2.5 ± 0.4 1.3 ± 0.6 4.8 ± 0.1 66.5 ± 27.0
PC3 4.7 ± 1.5 2.6 ± 0.4 5.6 ± 2.1 5.4 ± 1.2 123.8 ± 42.7 0.50 ± 0.04 7.3 ± 4.6 1.5 ± 0.8
MCF7 10.0 ± 0.5 6.5 ± 1.0 4.0 ± 0.9 5.9 ± 0.8 37.1 ± 4.9 0.7 ± 0.1 8.0 ± 3.0 1.1 ± 0.8
NB4 2.9 ± 0.7 1.8 ± 0.5 0.5 ± 0.2 1.2 ± 0.2 2.8 ± 0.2 0.2 ± 0.1 0.08 ± 0.04 2.7 ± 0.3
HL-60 3.5 ± 0.4 3.6 ± 0.3 0.8 ± 0.2 1.0 ± 0.3 3.3 ± 0.2 0.7 ± 0.3 0.2 ± 0.1 0.6 ± 0.5
BJ-hTERT 3.7 ± 0.4 2.8 ± 0.3 3.4 ± 0.5 3.4 ± 0.1 4.0 ± 0.6 0.8 ± 0.3 1.2 ± 0.4 2.6 ± 0.6
BJ-SV40T 2.9 ± 0.4 2.1 ± 0.4 2.9 ± 0.4 3.2 ± 0.4 2.8 ± 0.2 1.0 ± 0.4 0.7 ± 0.2 5.8 ± 0.7
BJ-
RASV12 2.9 ± 0.4 1.8 ± 0.7 4.0 ± 1.4 2.0 ± 0.7 3.3 ± 0.2 0.6 ± 0.2 1.1 ± 0.1 1.7 ± 0.8
HepG2: human hepatocellular carcinoma; SW480: human colon adenocarcinoma; U2OS: human osteosarcoma; HeLa: human cervical
carcinoma; PC3: human prostate adenocarcinoma; MCF7: human breast adenocarcinoma; NB4: human acute promyelocytic leukemia;
HL-60: human acute promyelocytic leukemia; BJ-hTERT: hTERT-immortalized skin non-malignant BJ; BJ-SV40T: SV40T-transformed
BJ-hTERT; BJ-RASV12: H-RAS V12-transformed BJ-SV40T. Extract numbers (10, 18, 37, 46, 57, and 58) can be identified from Table 1.
Due to the fact that Tetraclinis articulata (Vahl) Mast. extract (58) showed a high
cytotoxicity against several cancer cell lines, we acquired additional cancer cell lines from a
variety of tissues to further evaluate the activity of the extract. Fourteen human cancer cell
lines were treated with several concentrations of 58 for 96 h and cell viability was estimated
with the resazurin assay. Results show that this extract was cytotoxic against all the cancer
cell lines, with IC50 values in the range 4.3–4.9 µg/mL (Table 3).
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Figure 7. Cytotoxicity of selected plant extracts (10, 18, 37, 46, 57, and 58), cisplatin, and 5-FU against six cancer cell lines
derived from solid tumors and two acute promyelocytic leukemia cell lines. Cells were treated for 72 h, and cell viability
was evaluated with the resazurin assay.
Several types of phytochemicals may be involved in the selective anticancer activity
shown by the most active extracts. Cardiac glycosides may be responsible for the selective
cytotoxicity shown by the extracts from the leaves of Cascabela thevetia (L.) Lippold (10) and
the leaves of Digitalis purpurea L. (18). We, and others, have previously observed that plants
with cardiac glycosides, and several cardiac glycosides (e.g., digitoxin), induce potent
and selective cytotoxic effects against several types of cancer cells, including lung cancer
cells [15–23]. Isoquinoline alkaloids may participate in the cytotoxicity and selectivity
observed for the extract from the bulb of Pancratium maritimum L. (46) [24,25]. The cytotox-
icity and selectivity of our extract from the leaves of Taxus baccata L. (57) were probably
mediated by different taxane-type diterpenes, including paclitaxel [26,27]. Diterpenes (e.g.,
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ferruginol and sandaracopimaric acid.), monoterpenes (e.g., limonene and carveol), and
sesquiterpenes (e.g., β-caryophyllene and humulene) may participate in the cytotoxicity of
the extract from the leaves of Tetraclinis articulata (Vahl) Mast. [28–33].
Table 3. Cytotoxic activity of Tetraclinis articulata (Vahl) Mast. (58) against 14 cancer cell lines from a
variety of tissues.
Cell Line IC50 (Resazurin)(Media ± SEM, µg/mL)
58
A64-CLS 4.7 ± 0.3
AN3Ca 4.5 ± 0.9
Calu-1 4.7 ± 0.2
GAMG 4.5 ± 0.6
HNO97 4.5 ± 0.3
HT29 4.4 ± 0.4
KATO III 4.4 ± 0.7
MDA-MB-231 4.7 ± 0.2
MeWo 4.3 ± 0.2
PC-3 4.5 ± 1.0
Sk-Br-3 4.9 ± 0.0
Sk-OV-3 4.7 ± 0.1
T24 4.5 ± 0.3
UACC-62 4.5 ± 0.2
A64-CLS: submaxillary gland adenoma; AN3Ca: endometrial adenocarcinoma; Calu-1: squamous lung cancer;
GAMG: glioblastoma; HNO97: tongue cancer; HT29: colorectal cancer; KATO III: gastric cancer; MDA-MB-231:
triple-negative breast cancer; MeWo: BRAF wild-type melanoma; PC-3: prostate cancer; Sk-Br-3: HER2-positive
breast cancer; Sk-OV-3: ovarian cancer; UACC-62: BRAF mutant melanoma; and T24: bladder cancer.
In summary, because patients with advanced cancers need selective anticancer drugs,
we have searched for potential sources of selective anticancer drugs in a variety of plants.
After collecting 45 plants and preparing 65 extracts, we used a cancer cell line and a normal
cell line from the same tissue to detect selective cytotoxic activity [2–4]. Several extracts
induced selective cytotoxicity towards the cancer cell line, including extracts from Cascabela
thevetia (L.) Lippold (Apocynaceae), Frangula alnus Mill. (Rhamnaceae), Iberis ciliata subsp.
contracta (Pers.) Moreno (Brassicaceae), Juniperus macrocarpa Sm (Cupressaceae), Pancratium
maritimum L. (Amaryllidaceae), and Tetraclinis articulata (Vahl) Mast. (Cupressaceae). Due
to the fact that the selective anticancer activity of Tetraclinis articulata (Vahl) Mast was
high, we evaluated and observed cytotoxic activity in an additional 22 cancer cell lines,
representing the most common types of cancer. Our study shows that several plants are
promising sources for the isolation and the development of new anticancer drugs with
cancer-selective toxicity.
3. Materials and Methods
3.1. Plant Material
All plants were collected by F. García between November 2012 and April 2013 in sev-
eral areas of Sevilla, Cadiz, and Huelva (Andalusia, Spain). Collection was non-destructive
and plant specimens (5–110 g) were carefully selected to avoid any damage that could
affect the conservation of any species. A voucher specimen was deposited in the herbarium
at the CITIUS II Celestino Mutis (Center for Research, Technology, and Innovation of the
University of Seville). The botanical names, plant parts, and voucher specimen numbers
are listed in Table 1. Collection coordinates are provided in Table 4.
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Table 4. Collection coordinates of plants used in this work.
Extract Plant Name Collection Coordinates
1 Acis autumnalis (L.) Sweet 37◦14′22.06′′ N 6◦11′37.85′′ W
2–3 Anagallis monelli L. 36◦36′15.24′′ N 6◦16′2.76′′ W
4 Anthyllis hamosa Desf. 37◦04′25.2′′ N 6◦41′19.68′′ W
5–6 Aristolochia baetica L. 37◦14′16.68′′ N 6◦11′48.38′′ W
7 Armeria pungens (Link) Hoffmanns. & Link 37◦04′13.73′′ N 6◦41′16.97′′ W
8 Armeria velutina Welw. ex Boiss. & Reut. 37◦02′33.33′′ N 6◦35′53.85′′ W
9 Campanula lusitanica L. 37◦14′14.46′′ N 6◦11′55.8′′ W
10 Cascabela thevetia (L.) Lippold 37◦22′59.8′′ N 5◦59′27.36′′ W
11–13 Centaurea sphaerocephala L. 37◦05′40.18′′ N 6◦43′37.9′′ W
14–15 Cistus crispus L. 37◦14′22.06′′ N 6◦11′37.85′′ W
16 Cistus salvifolius L. 37◦14′19.74′′ N 6◦11′40.71′′ W
17 Cleome violacea L. 37◦14′23.37′′ N 6◦11′52.72′′ W
18 Digitalis purpurea L. 37◦27′30.78′′ N 6◦41′20.3′′ W
19–20 Dorycnium rectum (L.) Ser. 37◦20′14.71′′ N 5◦51′27.13′′ W
21 Echium gaditanum Boiss. 37◦04′11.69′′ N 6◦41′17.16′′ W
22–23 Elaeoselinum foetidum (L.) Boiss. 37◦14′15.72′′ N 6◦11′50.86′′ W
24–25 Erica arborea L. 37◦14′38.35′′ N 6◦11′49.92′′ W
26 Erophaca baetica (L.) Boiss. 37◦14′17.72′′ N 6◦11′46.41′′ W
27–28 Frangula alnus Mill. 37◦05′40.46′′ N 6◦43′34.47′′ W
29 Genista hirsuta M. Vahl 37◦14′16.70 “N 6◦11′49.05′′ W
30–31 Halimium calycinum (L.) K. Koch 37◦14′21.27N 6◦11′38.12′′ W
32–33 Halimium halimifolium (L.) Willk. 37◦14′23.43′′ N 6◦11′38.77′′ W
34–36 Hedysarum coronarium L. 36◦36′39.92′′ N 6◦16′46.6′′ W
37 Iberis ciliata subsp. contracta (Pers.) Moreno 37◦04′47.25′′ N 6◦41’13.82′′ W
38 Jasione montana L. 37◦13′45.76′′ N 6◦9′16.08′′ W
39–40 Juniperus macrocarpa Sm. 37◦04′13.53′′ N 6◦41′16.34′′ W
41 Malcolmia lacera (L.) DC. 37◦13′45.76′′ N 6◦9′16.08′′ W
42 Malva hispanica L. 37◦14′16.09′′ N 6◦11′51.89′′ W
43 Ononis subspicata Lag. 37◦04′45.90′′ N 6◦41′14.14′′ W
44 Ornithopus compressus L. 37◦13′45.76′′ N 6◦9′16.08′′ W
45 Ornithopus sativus Brot. 37◦13′45.76′′ N 6◦9′16.08′′ W
46 Pancratium maritimum L. 37◦04′11.14′′ N 6◦41′16.29′′ W
47–48 Pycnocomon rutifolium (Vahl) Hoffmanns. & Link 36◦36′12.69′′ N 6◦15′54.45′′ W
49 Ranunculus peltatus Schrank 37◦13′45.76′′ N 6◦9′16.08′′ W
50–52 Rhamnus lycioides subsp. oleoides (L.) Jahand. &Maire 37
◦14′25.18′′ N 6◦11′38.35′′ W
53 Scrophularia frutescens L. 37◦04′47.25′′ N 6◦41′13.82′′ W
54 Stauracanthus genistoides (Brot.) G. Sampaio 37◦04′44.55′′ N 6◦41′16.05′′ W
55–56 Tamarix canariensis Willd. 37◦15′45.64′′ N 5◦59′50.9′′ W
57 Taxus baccata L. 37◦22′27′′ N 5◦59′19′′ W
58 Tetraclinis articulata (Vahl) Mast. 37◦22′22.18′′ N 5◦59′10.75′′ W
59 Teucrium fruticans L. 37◦14′42.60′′ N 6◦11′52.78′′ W
60 Thymus mastichina (L.) L. 37◦02′33.33′′ N 6◦35′53.85′′ W
61 Tolpis barbata (L.) Gaertn. 37◦13′45.76′′ N 6◦9′16.08′′ W
62–63 Ulex parviflorus Pourr. subsp. parviflorus 37◦13′48.06′′ N 6◦1′31.4′′ W
64–65 Viburnum tinus L. 37◦22′27′′ N 5◦59′19′′ W
3.2. Preparation of the Extracts
Extracts were prepared within several hours after collecting the plants. Fresh plant
material (5–110 g) was extracted with 100–200 mL of ethanol/ethyl acetate/water (1:1:1)
at 60 ◦C for 1 h by using an ultrasound water bath apparatus. After vacuum filtration,
ethanol and ethyl acetate were eliminated in a rotary vacuum evaporator at 60 ◦C. Finally,
the remaining water solution was lyophilized to yield dried extracts. The extraction yield
(%) for each extract (see identification number in Table 1) was: 1 (1.9%), 2 (3.0%), 3 (5.6%),
4 (4.5%), 5 (0.9%), 6 (2.9%), 7 (5.9%), 8 (4.0%), 9 (2.7%), 10 (5.5%), 11 (2.0%), 12 (2.9%), 13
(3.5%), 14 (8.5%), 15 (5.2%), 16 (7.4%), 17 (8.9%), 18 (Nd), 19 (6.7%), 20 (7.2%), 21 (2.4%), 22
(1.9%), 23 (2.4%), 24 (6.0%), 25 (14.8%), 26 (3.3%), 27 (1.0%), 28 (4.4%), 29 (6.8%), 30 (10.6%),
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31 (4.9%), 32 (9.6%), 33 (4.6%), 34 (4.2%), 35 (4.0%), 36 (3.3%), 37 (4.2%), 38 (3.2%), 39 (5.9%),
40 (7.5%), 41 (5.3%), 42 (3.4%), 43 (2.7%), 44 (3.5%), 45 (2.4%), 46 (3.7%), 47 (2.6%), 48 (5.5%),
49 (0.9%), 50 (4.4%), 51 (5.5%), 52 (4.3%), 53 (5.8%), 54 (5.9%), 55 (Nd), 56 (8.4%), 57 (7.8%),
58 (5.5%), 59 (8.1%), 60 (6.5%), 61 (3.6%), 62 (10.7%), 63 (6.6%), 64 (9.0%), and 65 (9.9%). The
extracts were stored in dark glass bottles and kept in a cool dark place. The first cytotoxicity
experiment of the screening was carried out within the first month after preparing the
extracts to avoid the possible degradation of active compounds. In the first cytotoxicity
experiment, a stock solution of each extract was prepared in DMSO (100 mg/mL); a part of
this solution was diluted in culture medium and immediately used to treat the cells. The
stock solutions were aliquoted and frozen at −80 ◦C. The rest of independent cytotoxicity
experiments were carried out using different aliquots to avoid freeze–thaw cycles.
3.3. Chemicals and Cell Lines
Cisplatin, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), and
resazurin were bought from Sigma. MRC-5 (human fetal lung fibroblastic cells) and A549
(human non-small-cell lung cancer cells) were purchased from the European Collection of
Cell Cultures. MDA-MB-231 (human triple-negative breast cancer cells) was purchased
from the American Type Culture Collection (ATCC). UACC-62 (human BRAF mutant
melanoma cells) was obtained from National Cancer Institute. HepG2 (human hepatocel-
lular carcinoma cells), PC3 (human prostate cancer cells), HT29 (human colorectal cancer
cells), MCF7 (human breast cancer cells), HeLa (human cervical carcinoma cells), NB4
(human acute promyelocytic leukemia cells), HL-60 (human acute promyelocytic leukemia
cells), SW480 (human colon adenocarcinoma cells), and U2OS (human osteosarcoma cells)
were kindly provided by Dr. Helleday (Karolinska Institute, Sweden). HNO97 (human
tongue cancer cells), A64-CLS (human submaxillary gland adenoma cells), AN3Ca (hu-
man endometrial adenocarcinoma cells), Sk-OV-3 (human ovarian cancer cells), KATO III
(human gastric cancer cells), Sk-Br-3 (HER2-positive breast cancer cells), T24 (human blad-
der cancer cells), Calu-1 (human squamous lung cancer cells), and MeWo (human BRAF
wild-type melanoma cells) were purchased from Cell Lines Service (CLS). GAMG cells
(human glioblastoma cells) were provided by Dr. A. Ayala (University of Seville). BJ-hTERT
(hTERT-immortalized foreskin fibroblast BJ cells), BJ-SV40T (SV40T-transformed BJ-hTERT
cells), and BJ RASV12 (H-RAS V12-transformed BJ-SV40T cells) were provided by Dr. Hahn
(Dana-Farber Cancer Institute, USA) [14]. Cells were maintained in appropriate medium
and propagated according to standard protocols. MRC-5, A549, MDA-MB-231, HepG2,
HT29, MCF7, HeLa, SW48, U2OS, HNO97, A64-CLS, AN3Ca, SK-OV-3, Sk-Br-3, MeWo,
GAMG, BJ-hTERT, BJ-SV40T, and BJ-RASV12, were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) high-glucose medium. PC3 and T24 were grown in DMEM-
F12. UACC-62, NB4, HL60, and Calu-1 were maintained in RPMI 1640. KATO III were
grown in Ham’s F12. All media were supplemented with 100 U/mL penicillin, 100 µg/mL
streptomycin, and 10% fetal bovine serum. All cells were kept at 37 ◦C in a humidified
atmosphere containing 5% CO2. Cell culture reagents were purchased from Biowest.
3.4. Cell Viability Assays
Exponentially growing cells (3000–5000 cells per well) were seeded in 96-well plates
and were allowed to grow for 24 h. The cells were then exposed to several concentrations
of the extracts or the positive controls cisplatin and 5-fluorouracil. After a treatment period
of 72 h, cell viability was estimated with the MTT assay or the resazurin assay [2,15]. Due
to the fact that plant extracts contain compounds (e.g., polyphenols) that may interfere
with these assays, cell culture medium was removed before conducting these assays in all
adherent cell lines.
The MTT assay is based on the ability of viable cells to convert the MTT compound (3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) into an insoluble and purple
formazan product. After an incubation period of the cells with the MTT and a solubilization
step, the quantity of the colored product was measured with a plate reading spectropho-
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tometer. Dead cells are metabolically inactive and cannot produce the colored product.
Briefly, after the 72 h treatment period, the medium was removed, the cells were washed
with PBS, and 125 µL MTT (1 mg/mL in medium) was added to each well. The plates
were incubated for 4 h to allow viable cells to transform the MTT compound into an
insoluble formazan product. This insoluble compound was solubilized by adding 80 µL
20% SDS in 0.02M HCl to each well and by incubating the plates overnight at 37 ◦C. Finally,
optical densities were measured at 540 nm on a multi-well plate spectrophotometer reader
(Multiskan EX Labsystems, Vantaa, Finland).
The resazurin assay is a redox-based colorimetric or fluorometric assay based on the
capacity of viable cells to reduce the blue compound resazurin into the pink, fluorescent
and soluble product resorufin. The quantity of resorufin produced is proportional to the
number of viable cells. After treatment period, medium was removed and 150 µL of
resazurin (20 µg/mL in medium) was added to each well for 5–6 h. The absorbance was
measured at 540 nm and 620 nm on a multi-well plate spectrophotometer reader (Multiskan
EX Labsystems, Vantaa, Finland).
In both assays, cell viability was calculated as a percentage in relation to untreated
cells from at least two independent experiments. IC50 values were calculated by linear
regression analysis after selecting the two concentrations leading to cell viability values
immediately above and below 50%. With this approach, IC50 values always are within
the experimentally observed concentration range [15,34–37]. After estimating cell viability
and calculating IC50 values, results were expressed as mean ± standard error of the mean
(SEM), and a t-test (paired, two tailed) was used for statistical analysis. A p-value > 0.05
was not considered statistically significant and was not represented by any symbol. A
p-value≤ 0.05 was considered statistically significant and was represented with an asterisk,
two asterisks (p ≤ 0.01), or three asterisks (p ≤ 0.001). Since selectivity is the most relevant
parameter to detect anticancer potential in vitro [3,4], selectivity indices were used to
quantify this parameter. The selectivity index (S.I.) was calculated as the average of the
IC50 value in the normal cell line (MRC-5) divided by the IC50 value in the cancer cell line
(A549) obtained in each independent experiment [3].
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/plants10102193/s1. Figure S1: Comparison of cytotoxicity of Tetraclinis articulata (Vahl) Mast.
extract (58) assessed by MTT and resazurin assays. A549 and MRC-5 cells were treated for 72 h.
Figure S2: Tetraclinis articulata (Vahl) Mast. (Cupressaceae). General view of the plant (a) and the
plant material (b) used in the present study.
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